Horizon Therapeutics
| Formerly | Horizon Pharma plc |
|---|---|
| Company type | Subsidiary |
| Nasdaq: HZNP | |
| Industry | Pharmaceutical |
| Founded | 2005 |
| Headquarters |
|
Key people | Timothy P. Walbert (chairman, president & CEO) Paul W. Hoelscher (CFO) |
| Revenue | US$3.63 billion (2022) |
| US$617 million (2022) | |
| US$521 million (2022) | |
| Total assets | US$9.11 billion (2022) |
| Total equity | US$5.07 billion (2022) |
Number of employees | 2,115 (2022) |
| Parent | Amgen |
| Website | horizontherapeutics |
| Footnotes / references | |
Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.